Factors Associated with Medication Adherence to Long-Acting
                    Injectable Antipsychotics: Results from the STAR Network Depot
                    Study

Andrea Aguglia; Laura Fusar-Poli; Antimo Natale; Andrea Amerio; Irene Espa; Veronica Villa; Giovanni Martinotti; Giuseppe Carrà; Francesco Bartoli; Armando D’Agostino; Gianluca Serafini; Mario Amore; Eugenio Aguglia; Giovanni Ostuzzi; Corrado Barbui

doi:10.1055/a-1804-6211

Pharmacopsychiatry, Inhaltsverzeichnis

Pharmacopsychiatry 2022; 55(06): 281-289
DOI: 10.1055/a-1804-6211

Original Paper

Factors Associated with Medication Adherence to Long-Acting Injectable Antipsychotics: Results from the STAR Network Depot Study

Andrea Aguglia^*

¹Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Italy

²IRCCS Ospedale Policlinico San Martino, Genoa, Italy

,

Laura Fusar-Poli^*

³Department of Clinical and Experimental Medicine, Psychiatry Unit, University of Catania, Via Santa Sofia, Catania, Italy

,

Antimo Natale

³Department of Clinical and Experimental Medicine, Psychiatry Unit, University of Catania, Via Santa Sofia, Catania, Italy

,

Andrea Amerio

¹Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Italy

²IRCCS Ospedale Policlinico San Martino, Genoa, Italy

,

Irene Espa

¹Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Italy

²IRCCS Ospedale Policlinico San Martino, Genoa, Italy

,

Veronica Villa

¹Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Italy

²IRCCS Ospedale Policlinico San Martino, Genoa, Italy

,

Giovanni Martinotti

⁴Department of Neuroscience, Imaging and Clinical Sciences, “G. D’Annunzio” University of Chieti, Chieti, Italy

,

Giuseppe Carrà

⁵Department of Medicine and Surgery, University of Milano-Bicocca, via Cadore, Monza, Italy

⁶Division of Psychiatry, University College London, Tottenham Court Rd, Bloomsbury, London, United Kingdom

,

Francesco Bartoli

⁵Department of Medicine and Surgery, University of Milano-Bicocca, via Cadore, Monza, Italy

,

Armando D’Agostino

⁷Department of Health Sciences, University of Milan, Ospedale San Paolo, Blocco A, Via Antonio di Rudinì, Milan, Italy

,

Gianluca Serafini

¹Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Italy

²IRCCS Ospedale Policlinico San Martino, Genoa, Italy

,

Mario Amore

¹Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, Italy

²IRCCS Ospedale Policlinico San Martino, Genoa, Italy

,

Eugenio Aguglia

³Department of Clinical and Experimental Medicine, Psychiatry Unit, University of Catania, Via Santa Sofia, Catania, Italy

,

Giovanni Ostuzzi

⁸WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation; Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy

,

Corrado Barbui

⁸WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation; Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy

› Institutsangaben

Abstract

Introduction Long-acting injectable (LAI) antipsychotics are prescribed to people with severe psychiatric disorders who show poor adherence to oral medication. The present paper examined factors potentially associated with medication adherence to LAI treatment.

Methods The STAR (Servizi Territoriali Associati per la Ricerca) Network Depot Study was a multicenter, observational, prospective study that enrolled 461 subjects initiating a LAI from 32 Italian centers. After 6 and 12 months of treatment, we evaluated differences between participants with high (≥5 points) and low (<5 points) medication adherence using Kemp’s 7-point scale in sociodemographic, clinical, psychopathological, and drug-related variables. Factors that differed significantly between the two groups were entered for multivariate logistic regression.

Results Six months after enrollment, participants with high medication adherence were younger, living with other people, had lower Brief Psychiatric Rating Scale (BPRS) total scores, lower adverse events, and a more positive attitude toward medication than participants with low adherence. Multivariate regression confirmed lower BPRS resistance and activation scores, absence of adverse events, and positive attitude toward medication as factors significantly associated with good adherence. After 12 months, all BPRS subscales were significantly lower in the high adherence group, which also showed a more positive attitude toward medication. BPRS resistance and attitude toward medication were confirmed as factors associated with medication adherence.

Discussion Our findings suggest that adherence to LAI is principally related to attitude toward medication and traits of suspiciousness/hostility. Quality of patient-clinician relationship and tailored psychoeducational strategies may positively affect adherence in people undergoing psychopharmacological treatment, including LAI.

Key words

long-acting injectable - antipsychotics - adherence - schizophrenia - bipolar disorder

Volltext

Referenzen

References
1 Haynes RB. Compliance in health care. Baltimore, MD: Johns Hopkins University Press; 1979
2 Myers LB, Midence K. Adherence to treatment in medical condition. Amsterdam: Harwood Academic Publisher; 1998
3 Chakrabarti S. What’s in a name? Compliance, adherence and concordance in chronic psychiatric disorders. World J Psychiatry 2014; 4: 30-36
4 Fiorillo A, Barlati S, Bellomo A. et al. The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: A clinical review. Ann Gen Psychiatry 2020; 19: 43
5 Pacchiarotti I, Tiihonen J, Kotzalidis GD. et al. Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review. Eur Neuropsychopharmacol 2019; 29: 457-470
6 Velligan DI, Sajatovic M, Hatch A. et al. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence 2017; 11: 449-468
7 Marazziti D, Mucci F, Avella MT. et al. The increasing challenge of the possible impact of ethnicity on psychopharmacology. CNS Spectr 2021; 26: 222-231
8 Fleck DE, Keck PE, Corey KB. et al. Factors associated with medication adherence in African American and white patients with bipolar disorder. J Clin Psychiatry 2005; 66: 646-652
9 Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: Epidemiology, contributing factors and management strategies. World Psychiatry 2013; 12: 216-226
10 Kretchy IA, Osafo J, Agyemang SA. et al. Psychological burden and caregiver-reported non-adherence to psychotropic medications among patients with schizophrenia. Psychiatry Res 2018; 259: 289-294
11 Yatham LN, Kennedy SH, Parikh SV. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018; 20: 97-170
12 Benkert O, Graf-Morgenstern M, Hillert A. et al. Public opinion on psychotropic drugs: An analysis of the factors influencing acceptance or rejection. J Nerv Ment Dis 1997; 185: 151-158
13 Helbling J, Ajdacic-Gross V, Lauber C. et al. Attitudes to antipsychotic drugs and their side effects: A comparison between general practitioners and the general population. BMC Psychiatry 2006; 6: 42
14 Sajatovic M, Jenkins JH. Is antipsychotic medication stigmatizing for people with mental illness?. Int Rev Psychiatry 2007; 19: 107-112
15 Janssen B, Gaebel W, Haerter M. et al. Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders. Psychopharmacology (Berl) 2006; 187: 229-236
16 Leclerc E, Mansur RB, Brietzke E. Determinants of adherence to treatment in bipolar disorder: A comprehensive review. J Affect Disord 2013; 149: 247-252
17 El-Missiry A, Elbatrawy A, El Missiry M. et al. Comparing cognitive functions in medication adherent and non-adherent patients with schizophrenia. J Psychiatr Res 2015; 70: 106-112
18 Foglia E, Schoeler T, Klamerus E. et al. Cannabis use and adherence to antipsychotic medication: A systematic review and meta-analysis. Psychol Med 2017; 47: 1691-1705
19 El Abdellati K, De Picker L, Morrens M. Antipsychotic treatment failure: A systematic review on risk Factors and interventions for treatment adherence in psychosis. Front Neurosci 2020; 14: 531763
20 Dibonaventura M, Gabriel S, Dupclay L. et al. A patient perspective of the impact of medication side effects on adherence: Results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry 2012; 12: 20
21 Carbon M, Correll CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci 2014; 16: 505-524
22 García S, Martínez-Cengotitabengoa M, López-Zurbano S. et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: A systematic review. J Clin Psychopharmacol 2016; 36: 355-371
23 Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002; 63: 1121-1128
24 McCann TV, Boardman G, Clark E. et al. Risk profiles for non-adherence to antipsychotic medications. J Psychiatr Ment Health Nurs 2008; 15: 622-629
25 Firth J, Siddiqi N, Koyanagi A. et al. The Lancet Psychiatry Commission: A blueprint for protecting physical health in people with mental illness. Lancet Psychiatry 2019; 6: 675-712
26 Day JC, Bentall RP, Roberts C. et al. Attitudes toward antipsychotic medication: The impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry 2005; 62: 717-724
27 McCabe R, Healey PG, Priebe S. et al. Shared understanding in psychiatrist-patient communication: Association with treatment adherence in schizophrenia. Patient Educ Couns 2013; 93: 73-79
28 Correll CU, Kim E, Sliwa JK. et al. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: An overview. CNS Drugs 2021; 35: 39-59
29 Bertolini F, Ostuzzi G, Pievani M. et al. Comparing long-acting antipsychotic discontinuation rates under ordinary clinical circumstances: A survival analysis from an observational, pragmatic study. CNS Drugs 2021; 35: 655-665
30 Peuskens J, Olivares JM, Pecenak J. et al. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin 2010; 26: 501-509
31 Acosta FJ, Hernández JL, Pereira J. et al. Medication adherence in schizophrenia. World J Psychiatry 2012; 2: 74-82
32 von Elm E, Altman DG, Egger M. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 344-349
33 World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191-2194
34 Ostuzzi G, Mazzi MA, Terlizzi S. et al. Factors associated with first-versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy. PLoS One 2018; 13: e0201371
35 Barbui C, Bertolini F, Bartoli F. et al. Reasons for initiating long-acting antipsychotics in psychiatric practice: Findings from the STAR Network Depot Study. Ther Adv Psychopharmacol 2020; 10: 2045125320978102
36 Bartoli F, Ostuzzi G, Crocamo C. et al. Clinical correlates of paliperidone palmitate and aripiprazole monohydrate prescription for subjects with schizophrenia-spectrum disorders: Findings from the STAR Network Depot Study. Int Clin Psychopharmacol 2020; 35: 214-220
37 Aguglia A, Fusar-Poli L, Amerio A. et al. The Role of attitudes toward medication and treatment adherence in the clinical response to LAIs: Findings from the STAR Network Depot Study. Front Psychiatry 2021; 12: 784366
38 Bartoli F, Cavaleri D, Callovini T. et al. Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: Findings from the STAR Network Depot Study. Psychiatry Res 2022; 309: 114405
39 Kemp R, Hayward P, Applewhaite G. et al. Compliance therapy in psychotic patients: Randomised controlled trial. BMJ 1996; 312: 345-349
40 Shafer A. Meta-analysis of the brief psychiatric rating scale factor structure. Psychol Assess 2005; 17: 324-335
41 Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity. Psychol Med 1983; 13: 177-183
42 Rossi A, Arduini L, De Cataldo S. et al. Subjective response to neuroleptic medication: A validation study of the Italian version of the Drug Attitude Inventory (DAI). Epidemiol Psichiatr Soc 2001; 10: 107-114
43 Marrero RJ, Fumero A, de Miguel A. et al. Psychological factors involved in psychopharmacological medication adherence in mental health patients: A systematic review. Patient Educ Couns 2020; 103: 2116-2131
44 Wiesjahn M, Jung E, Lamster F. et al. Explaining attitudes and adherence to antipsychotic medication: The development of a process model. Schizophr Res Treatment 2014; 2014: 341545
45 Soria CG, Velasco CF, Martín LF. et al. Attitude toward medication as a predictor of therapeutic adherence. Importance of psychoeducation on treatment. Eur Psychiatry 2016; 33: S565-S566
46 Sajatovic M, Levin JB, Ramirez LF. et al. Long-acting injectable antipsychotic medication plus customized adherence enhancement in poor adherence patients with bipolar disorder. Prim Care Companion CNS Disord 2021; 23: 20m02888
47 Mbwambo J, Kaaya S, Lema I. et al. An interventional pilot of customized adherence enhancement combined with long-acting injectable antipsychotic medication (CAE-L) for poorly adherent patients with chronic psychotic disorder in Tanzania. BMC Psychiatry 2022; 22: 62
48 Kikkert MJ, Schene AH, Koeter MW. et al. Medication adherence in schizophrenia: Exploring patients', carers' and professionals’ views. Schizophr Bull 2006; 32: 786-794
49 Mintz DL. Teaching the prescriber's role: The psychology of psychopharmacology. Acad Psychiatry 2005; 29: 187-194
50 Velligan DI, Weiden PJ, Sajatovic M. et al. The expert consensus guideline series: Adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009; 70: 1-46
51 Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: Challenges and management strategies. Patient Relat Outcome Meas 2014; 5: 43-62
52 Rodolico A, Bighelli I, Avanzato C. et al. Family interventions for relapse prevention in schizophrenia: A systematic review and network meta-analysis. Lancet Psychiatry. 2022 S2215-0366(21)00437-5 [Epub ahead of print]